

Global Pharma Partners										
	2021	2022	2023	2024	2025	2026	TV			
Revenue from 42 Licensed Products	\$ 1,437,102	\$ 3,968,637	\$ 5,683,700	\$ 8,804,834	\$ 18,004,955	\$ 19,407,866	\$ 42,850,307			
Attrition-potential	25% \$ (359,275)	\$ (992,159)	\$ (1,420,925)	\$ (2,201,209)	\$ (4,501,239)	\$ (4,851,967)	\$ (10,712,577)			
Post attrition Cash Flow (CF)	\$ 1,077,826	\$ 2,976,478	\$ 4,262,775	\$ 6,603,626	\$ 13,503,716	\$ 14,555,900	\$ 32,137,731			
Cumulative CF	\$ 75,118,051									
Discount Rate	25%									
		Attrition/non-approval/non-move forward of drugs Rate								
DCF NPV	\$22,635,003	5%	10%	20%	25%	30%	35%	40%	45%	50%
Discount Rate		5%	10%	20%	25%	30%	35%	40%	45%	50%
		\$ 72,356,376	\$ 68,548,146	\$ 60,931,685	\$ 57,123,455	\$ 53,315,225	\$ 49,506,994	\$ 45,698,764	\$ 41,890,534	\$ 38,082,303
		\$ 56,044,554	\$ 53,094,841	\$ 47,195,414	\$ 44,245,701	\$ 41,295,987	\$ 38,346,274	\$ 35,396,560	\$ 32,446,847	\$ 29,497,134
		\$ 44,149,397	\$ 41,825,744	\$ 37,178,439	\$ 34,854,787	\$ 32,531,135	\$ 30,207,482	\$ 27,883,830	\$ 25,560,177	\$ 23,236,525
		\$ 35,323,941	\$ 33,464,787	\$ 29,746,477	\$ 27,887,322	\$ 26,028,167	\$ 24,169,013	\$ 22,309,858	\$ 20,450,703	\$ 18,591,548
		\$ 28,671,003	\$ 27,162,003	\$ 24,144,003	\$ 22,635,003	\$ 21,126,002	\$ 19,617,002	\$ 18,108,002	\$ 16,599,002	\$ 15,090,002
		\$ 23,581,485	\$ 22,340,354	\$ 19,858,092	\$ 18,616,961	\$ 17,375,831	\$ 16,134,700	\$ 14,893,569	\$ 13,652,438	\$ 12,411,308